RNLXY · Renalytix plc
$4.15
-0.34 (-7.47%)
At close · Sep 4
Going-concern doubt
— flagged Nov 19, 2024
Substantial doubt about the company's ability to continue as a going concern.
“As a result of the Company's losses and its projected cash needs, as defined in the accounting literature, substantial doubt exists about the Company's ability to continue as a going concern. While subsequent to September 30, 2024, the company has successfully raised approximately $14.9 million, net of expenses, in new equity capital and restructured the existing long-term debt recorded on the balance sheet, the Company does have a history of operating losses and it has been expensive to deliver all of the milestones to commercialize the kidneyintelX.dkd test. … As such, management has concluded that there is a going concern uncertainty. The consolidated financial statements do not include any adjustments that may result from the outcome of this going concern uncertainty.”View the 10-Q filed Nov 19, 2024
Market Cap
$2.20M
Shares
529,930
RNLXY metrics
48 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$4.15
Market cap
$2.20M
Price action
19 metricsPrice change (1W)
+56.0%
Price change (30D)
+49.8%
Price change (3M)
+244.4%
Price change (6M)
+77.4%
Price change (YTD)
+14.6%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
120.1%
Beta
-0.1
RSI (14D)
72.2
Price vs SMA 50
+82.1%
Price vs SMA 200
—
Avg volume (3M)
7,623
Relative volume
0.7
Average dollar volume
$18,741
Company
3 metricsSector
Healthcare
Industry
Health Information Services
Shares outstanding
529,930
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.9×
reciprocal yield 106.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1,274.5%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-05-15
Profitability
9 metricsGross margin
12.7%
Operating margin
-1,054.9%
Trailing 12 months
Net margin
-1,191.8%
Gross profit (TTM)
$299,000
Operating profit (TTM)
−$24.81M
Net income (TTM)
−$28.03M
Trailing 12 months
Diluted EPS (TTM)
$-150.00
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+13.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.5%
Year over year · more shares
Revenue CAGR (3Y)
+15.4%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-584.7%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
−$24.52M
Free cash flow (TTM)
—
Quick ratio
0.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$909,000
Total assets
$4.79M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$24.44M
Capital expenditures (TTM)
$0
R&D (TTM)
$7.42M
SG&A (TTM)
—
Stock compensation (TTM)
$1.44M
R&D / revenue
315.6%
Stock compensation / revenue
61.3%
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
53 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged